Merck KGaA, Darmstadt, Germany: Multiple Sclerosis, Relapsing-Remitting trials

The registry lists 39 Multiple Sclerosis, Relapsing-Remitting studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 2 6Phase 3 8Phase 4 8No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)CompletedNCT04997148Results posted
• Study of Evobrutinib in Participants With RMSTerminatedNCT04032171Phase 3Results posted
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedNCT04032158Phase 3Results posted
• A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)TerminatedNCT03387046Phase 2Results posted
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedNCT02975349Phase 2Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4Results posted
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2Results posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]TerminatedNCT01134627Phase 2Results posted
• CLARITY Extension StudyCompletedNCT00641537Phase 3Results posted
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisCompletedNCT00441103Phase 3Results posted
• RNF and Betaseron® Tolerability StudyCompletedNCT00428584Phase 3Results posted
• Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisCompletedNCT00367484Phase 4Results posted
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesCompletedNCT03284970
• Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)TerminatedNCT02394782
• A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNCT01142583
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNCT01142518
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNCT01142492
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNCT01142453
• An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyCompletedNCT01141751
• A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) SubjectsCompletedNCT01125475
• An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These ParametersCompletedNCT01112345
• An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)CompletedNCT01110993
• An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.CompletedNCT01108887
• Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)CompletedNCT01080053
• To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis PatientsCompletedNCT01080040
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)CompletedNCT01080027
• A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in ArgentinaCompletedNCT01080001
• Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®CompletedNCT01075880
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
• Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsCompletedNCT00292253Phase 3
• Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4